H

Hana Pharm Co Ltd
KRX:293480

Watchlist Manager
Hana Pharm Co Ltd
KRX:293480
Watchlist
Price: 11 010 KRW 0.82% Market Closed
Market Cap: 190.5B KRW
Have any thoughts about
Hana Pharm Co Ltd?
Write Note

Relative Value

The Relative Value of one Hana Pharm Co Ltd stock under the Base Case scenario is 19 987.79 KRW. Compared to the current market price of 11 010 KRW, Hana Pharm Co Ltd is Undervalued by 45%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
19 987.79 KRW
Undervaluation 45%
Relative Value
Price
H
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
98
vs Industry
71
Median 3Y
1.2
Median 5Y
1.6
Industry
2.5
Forward
0.8
vs History
95
vs Industry
37
Median 3Y
10.6
Median 5Y
10.9
Industry
21.8
Forward
8.1
vs History
96
vs Industry
39
Median 3Y
10
Median 5Y
11.2
Industry
16.1
vs History
33
vs Industry
27
Median 3Y
19
Median 5Y
-28.8
Industry
23.8
vs History
98
vs Industry
67
Median 3Y
0.9
Median 5Y
1.2
Industry
2.1
vs History
98
vs Industry
71
Median 3Y
1.2
Median 5Y
1.4
Industry
2.7
Forward
0.9
vs History
98
vs Industry
74
Median 3Y
1.9
Median 5Y
2.1
Industry
5.2
vs History
42
vs Industry
42
Median 3Y
7
Median 5Y
7
Industry
13.5
Forward
6.1
vs History
11
vs Industry
40
Median 3Y
8.5
Median 5Y
8.5
Industry
16.8
Forward
7.9
vs History
82
vs Industry
40
Median 3Y
10.2
Median 5Y
10.1
Industry
15.2
vs History
47
vs Industry
28
Median 3Y
11.9
Median 5Y
17.8
Industry
19.3
vs History
98
vs Industry
68
Median 3Y
0.8
Median 5Y
1.1
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Hana Pharm Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Hana Pharm Co Ltd
KRX:293480
190.5B KRW 0.8 9.7 7.1 9.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
729.3B USD 17.8 87.1 46.9 52.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK 9.6 27.5 19.1 21.8
US
Johnson & Johnson
NYSE:JNJ
347.8B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
248.3B USD 3.9 20.4 10.3 12.4
CH
Roche Holding AG
SIX:ROG
197.2B CHF 3.4 17.2 9.7 11.5
UK
AstraZeneca PLC
LSE:AZN
159B GBP 4.1 31 169.2 253.5
CH
Novartis AG
SIX:NOVN
169.7B CHF 3.8 10.8 9.4 13
US
Pfizer Inc
NYSE:PFE
149.4B USD 2.5 35.1 10.5 15.8
P/S Multiple
Revenue Growth P/S to Growth
KR
H
Hana Pharm Co Ltd
KRX:293480
Average P/S: 382 941.9
0.8
24%
0
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
17.8
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
3.9
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
KR
H
Hana Pharm Co Ltd
KRX:293480
Average P/E: 29.2
9.7
21%
0.5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
87.1
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
27.5
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.4
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.2
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.1
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
H
Hana Pharm Co Ltd
KRX:293480
Average EV/EBITDA: 414
7.1
16%
0.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.9
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.3
331%
0
CH
Roche Holding AG
SIX:ROG
9.7
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.2
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
H
Hana Pharm Co Ltd
KRX:293480
Average EV/EBIT: 1 810.7
9.6
18%
0.5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.3
211%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
21.8
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.5
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.5
131%
1.9
CH
Novartis AG
SIX:NOVN
13
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2

See Also

Discover More
Back to Top